Amarin
Amarin files replacement universal shelf registration statement
Published in Pharma Investments, Ventures and Law Weekly, August 13th, 2006
Amarin Corp. plc (AMRN), the London-based neuroscience company, announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that will, if declared effective by the SEC, allow the company to issue and sell from time to time up to $100 million of its ordinary shares, preference shares, warrants, purchase contracts and/or debt securities (including convertible debt securities), either individually or as units, in one or more offerings.
If the SEC declares the universal shelf registration statement effective, the company will retire the unused portion of its previous shelf registration statement that was declared...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Alder Biopharmaceuticals
Alder Biopharmaceuticals completes series B financing - Alteon
Alteon research collaborator receives funding for diabetic complications study - Amarin
Amarin lists on AIM and IEX - Array BioPharma
Array BioPharma receives $18M from Boulder facilities transaction - Avitar
Avitar completes $750,000 financing - Cenveo
Cenveo, Inc. acquires Rx Label Technology Corporation - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
